Precision destruction of disease-causing proteins.Broad patient impact.
Learn MoreC4T’s platform uses a combination of proprietary assays and analytical techniques that allows for optimization of our degraders over multiple dimensions to control key parameters.
Stew Fisher, Ph.D. (CSO)
With their strong science and world class team we have no doubt that C4T will be able to bring powerful new therapeutics to patients and we are excited to collaborate with a pioneer in this promising new protein degradation space.
Adam Stone, Chief Investment Officer, Perceptive
C4T is as differentiated as differentiated gets.
FUND MANAGER
We are thrilled to be investors with the pioneering team at C4T. They have applied their deep chemistry expertise to the exciting field of protein degradation and are generating an exciting pipeline of novel and potentially best-in-class medicines. We feel right at home with their science-first approach and believe the C4T team will be among the leaders in the field.
Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP
Our science
Targeted protein degradation harnesses the cell’s innate capability to control protein levels to remove known drivers of disease
